



LAO PEOPLE 'S DEMOCRATIC REPUBLIC
PEACE INDEPENDENCE DEMOCRACY UNITY PROSPERITY

MINISTRY OF HEALTH
FOOD AND DRUG DEPARTMENT
TEL (856 21) 214013, 214014
FAX: (856 21) 214015.

Certificate of Drug Registration

Registration Number:07-LM-10049-26

ALIENCOFENIZ

Dosage Form	CAPSULE
Active Ingredients	ENCORAFENIB 75 mg
Description	The contents is a White capsule shell, and its contents are white to almost white powder, HDPE Bottle, 60 capsules per bottle.
Size of packaging unit	60 CAPSULES
Indications	See Annex
Manufacturer	LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY SAYSETHA DEVELOPMENT ZONE, SAYSETHA DISTRICT, VIENTIANE CAPITAL, LAO PDR

This Certificate is issued to attest that the product described above has met the minimum standards required for drug registration undertaken by the Food and Drug Department in Lao PDR.

This certificate expires, unless previously suspended or revoked, on **15 July 2031**

Note: All boxes and packaging for importations must bear the Lao Registration No. **07-LM-10049-26**

At, Vientiane, **15 July 2026**



ນ.ພຸດທະວັນ ອິນລິຄຳ



Registration Number:07-LM-10049-26

ALIENCOFENIZ

ANNEX

INDICATIONS

ALIENCOFENIZ is a kinase inhibitor indicated:

Melanoma

- in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Colorectal Cancer (CRC)

- in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.

Non-Small Cell Lung Cancer (NSCLC)

- in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.

ALIENCOFENIZ ເປັນສານປັບປຸງ kinase ສໍາລັບການປິ່ນປົວ:

ມະເຮັງຜິວໜັງຊະນິດ ເມລາໂນມາ (melanoma):

- ໃຊ້ຮ່ວມກັບ binimetinib ສໍາລັບການປິ່ນປົວຄົນເຈັບທີ່ເປັນມະເຮັງຜິວໜັງ ທີ່ບໍ່ສາມາດຜ່າຕັດອອກໄດ້ ຫຼື ມີການແຜ່ລາມ ດ້ວຍການກາຍພັນ BRAF V600E ຫຼື V600K.

ມະເຮັງລໍາໄສ້ໃຫຍ່ (CRC):

- ໃຊ້ຮ່ວມກັບ binimetinib ແລະ mFOLFOX6 ເພື່ອປິ່ນປົວຄົນເຈັບທີ່ເປັນມະເຮັງລໍາໄສ້ໃຫຍ່ ທີ່ມີການແຜ່ລາມ ດ້ວຍການກາຍພັນ BRAF V600E ຫຼື V600K.

ມະເຮັງປອດຊະນິດທີ່ບໍ່ແມ່ນຈຸລັງຂະໜາດນ້ອຍ (NSCLC):

- ໃຊ້ຮ່ວມກັບ binimetinib ເພື່ອປິ່ນປົວຄົນເຈັບທີ່ເປັນມະເຮັງປອດຊະນິດທີ່ບໍ່ແມ່ນຈຸລັງຂະໜາດນ້ອຍ (NSCLC) ທີ່ມີການກາຍພັນ BRAF V600E.